Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA mechanisms: tissues, immune signals and bone

Follow inflammation from the tissue where symptoms arise to the signals that targeted treatments interrupt. A useful model of psoriatic arthritis leaves room for differences between skin, joints and the spine.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 17 of 21

The essentials

PsA involves a network of immune cells and tissue responses. A painful site, a cytokine level and a drug target describe different parts of that network; none alone identifies the best treatment.

Start with the tissue

A joint is more than two bone ends. Its lining, tendon sheaths and nearby attachment sites can become inflamed together or separately. This helps explain why swollen joints, heel pain and a swollen whole finger feel different. 1

Start with the tissue
Tissue or termWhat it means
Synovium / synovitisThe joint's inner lining / inflammation of that lining.
Enthesis / enthesitisWhere a tendon or ligament attaches to bone / inflammation at the attachment.
Tendon sheath / tenosynovitisThe sleeve around some tendons / inflammation of that sleeve.
DactylitisSwelling of an entire digit, involving several adjacent structures rather than one joint alone.
Axial diseaseInflammatory involvement of the spine or sacroiliac joints; evidence from peripheral joints cannot simply be transferred to it.

What do IL-23, IL-17 and TNF mean?

Cytokines are messages exchanged between cells. IL-23 supports certain immune responses that produce IL-17; IL-17A, IL-17F and TNF can amplify local inflammation. Structural cells also respond and send signals back. This is a network with feedback, rather than a single switch. 18

The familiar IL-23 → IL-17 diagram is a teaching simplification. Not all IL-17 production depends on IL-23, and a pathway's importance can differ between tissues. A laboratory mechanism does not establish a treatment's benefit for every manifestation.

The skin offers a visible example

In Olga Goodman's article, the plaque is explained as a feedback loop between immune cells and keratinocytes, the main cells of the epidermis. Immune signals accelerate skin-cell turnover; activated skin cells attract further inflammation. This patient adaptation uses that part of the author's explanation. 19

Skin and joint disease share pathways, but clearing plaques does not by itself demonstrate control of arthritis or spinal inflammation. The linked English article also discusses drug mechanisms across rheumatology; that broader list is not a menu of PsA treatments.

Why erosion and new bone can coexist

Bone is continually removed and rebuilt. In PsA, inflammatory signals and altered tissue repair may produce both local bone loss, called erosion, and additional bone formation. The same person can have both. 1, 18

Reducing inflammation can protect future function. It does not mean established structural changes instantly disappear. Pain, current inflammatory activity and accumulated damage therefore need separate assessment.

How this helps explain treatment

Biologic medicines can intercept selected signals outside cells; other targeted medicines influence signaling inside cells. A shared target helps explain a drug class, while trials establish what that class actually achieves. 3

The useful next question is: which manifestations need treatment, and what evidence supports this mechanism for those manifestations? Skin, peripheral joints, entheses, bowel inflammation and the eyes may influence the answer.

Go deeper

What a tissue study can—and cannot—show

Researchers can examine which cells are present and which genes are active in a biopsy before and after treatment. EBIO studied entheseal tissue in a small cohort of 10 people. Such work connects clinical change to biology; it does not provide a routine biopsy algorithm for choosing everyone's drug. 16

A cytokine is a messenger protein; a receptor receives its signal; a signaling pathway carries the message inside the cell. A gene-expression signature records patterns of activity. These terms describe different measurements, not interchangeable tests.

Questions for your visit

  1. Which tissue is the main source of my current symptoms?
  2. Are we measuring active inflammation, damage or both?
  3. Why is this treatment mechanism a good fit for the manifestations that matter to me?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Dates identify the cited publications. Protocols, exploratory analyses and clinical results answer different questions. This is a selected reading route, not a complete evidence review.

  1. NIAMS. Psoriatic arthritis: overview and causes.
  2. EULAR recommendations for PsA: 2023 update (published 2024).
  3. EBIO. Entheseal tissue response to IL-17A inhibition; biopsy study (online 2025).
  4. Human spinal enthesis: comparative biology of IL-17F and IL-17A (2025).
  5. Olga Goodman, MD. Psoriasis From the Inside Out (18 June 2026). Author's educational article.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medical researchPsoriasisPsoriatic arthritisSpondyloarthritis